FDA Grants Accelerated Approval to Rocket Pharmaceuticals' KRESLADI for Severe Pediatric LAD-I
Rocket Pharmaceuticals saw its stock climb after the U.S. Food and Drug Administration gave accelerated approval to KRESLADI, an autologous hematopoietic stem cell-based gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) who lack an HLA-matched sibling donor for allogeneic transplant. The approval is based on bi…